Login Register Cart 0
Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Expression and Clinical Significance of Microtubule-Actin Cross-Linking Factor 1 in Serous Ovarian Cancer

Author(s): Longyang Liu, Ke Hu, Zhaoyang Zeng, Caiqiu Xu, Jin Lv, Zhongqiu Lin and Bin Wen*

Volume 16, Issue 1, 2021

Published on: 11 February, 2021

Page: [66 - 72] Pages: 7

DOI: 10.2174/1574892816666210211091543

Price: $65

Abstract

Background: Ovarian Cancer (OC) remains the first leading cause of gynecologic malignancy. The survival rate from Serous Ovarian Cancer (SOC) is very low, and the present prognostic predictors of SOC are not very sensitive or specific.

Objective: The present study aimed to investigate Microtubule-Actin Cross-Linking Factor 1 (MACF1) expression in SOC tissues (including paraffin-embedded and fresh tissues) and to assess its expression and significant value in patients with SOC.

Methods: A total of 18 fresh SOC tissues and their paired paratumor tissues were performed with reverse-transcription quantitative PCR analysis to detect MACF1 mRNA expression. Moreover, 175 paraffin-embedded SOC tissues and 41 paratumor tissues were assessed for MACF1 expression using immunohistochemistry.

Results: The mRNA and protein expression of MACF1, both were higher in cancer tissues than that in paratumor tissues, and the high expression of MACF1 was associated with shorter Recurrence Free Survival (RFS) and Overall Survival (OS) in patients with SOC. Furthermore, multivariate regression analysis showed that high MACF1 expression was an independent poor survival predictor of patients with SOC.

Conclusion: MACF1 is upregulated in SOC, and it may be used as a useful prognostic biomarker in SOC.

Keywords: Microtubule-actin cross-linking factor 1, ovarian cancer, overall survival, prognosis, recurrence-free survival, serous ovarian cancer.

« Previous Next »
[1]
Taylor KN, Eskander RN. PARP inhibitors in epithelial ovarian cancer. Recent Pat Anticancer Drug Discov 2018; 13(2): 145-58.
[http://dx.doi.org/10.2174/1574892813666171204094822] [PMID: 29205122]
[2]
Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin 2019; 69(4): 280-304.
[http://dx.doi.org/10.3322/caac.21559] [PMID: 31099893]
[3]
Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin 2018; 68(4): 284-96.
[http://dx.doi.org/10.3322/caac.21456] [PMID: 29809280]
[4]
Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2018; 68(4): 297-316.
[http://dx.doi.org/10.3322/caac.21446] [PMID: 29846940]
[5]
Weberpals JI, Koti M, Squire JA. Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer. Cancer Genet 2011; 204(10): 525-35.
[http://dx.doi.org/10.1016/j.cancergen.2011.09.004] [PMID: 22137482]
[6]
Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet 2014; 384(9951): 1376-88.
[http://dx.doi.org/10.1016/S0140-6736(13)62146-7] [PMID: 24767708]
[7]
Liu L, Yi J, Yuan J, et al. FOXO1 overexpression is correlated with poor prognosis in epithelial ovarian cancer. Cancer Biomark 2020; 28(1): 1-8.
[http://dx.doi.org/10.3233/CBM-182119] [PMID: 32224523]
[8]
Zeng Z, Ji N, Yi J, et al. LGR4 overexpression is associated with clinical parameters and poor prognosis of serous ovarian cancer. Cancer Biomark 2020; 28(1): 65-72.
[http://dx.doi.org/10.3233/CBM-191145] [PMID: 32176632]
[9]
Liu L, Yi J, Deng X, et al. MYH9 overexpression correlates with clinicopathological parameters and poor prognosis of epithelial ovarian cancer. Oncol Lett 2019; 18(2): 1049-56.
[http://dx.doi.org/10.3892/ol.2019.10406] [PMID: 31423165]
[10]
Yao Y, Liu L, He W, et al. Low expression of KIF7 indicates poor prognosis in epithelial ovarian cancer. Cancer Biomark 2019; 26(4): 481-9.
[http://dx.doi.org/10.3233/CBM-190328] [PMID: 31658044]
[11]
Podust V. Biomarker for ovarian and endometrial cancer: Hepcidin. US7510842, 2009.
[12]
Mansfield BC, Yip PF, Amonkar S, Bertenshaw GP. Predictive biomarkers for ovarian cancer. US10605811, 2020.
[13]
Quick QA. Microtubule-actin crosslinking factor 1 and Plakins as therapeutic drug targets. Int J Mol 2018; 19(2): 368.
[http://dx.doi.org/10.3390/ijms19020368] [PMID: 29373494]
[14]
Afghani N, Mehta T, Wang J, Tang N, Skalli O, Quick QA. Microtubule actin cross-linking factor 1, a novel target in glioblastoma. Int J Oncol 2017; 50(1): 310-6.
[http://dx.doi.org/10.3892/ijo.2016.3798] [PMID: 27959385]
[15]
Van Criekinge W, Straub J. Detection and prognosis of lung cancer. US20170121775, 2017.
[16]
Bonner K, Borlay D, Kutten O, Quick QA. Inhibition of the Spectraplakin protein microtubule actin crosslinking factor 1 sensitizes glioblastomas to radiation. Brain Tumor Res Treat 2020; 8(1): 43-52.
[http://dx.doi.org/10.14791/btrt.2020.8.e1] [PMID: 32390353]
[17]
Del Valle PR, Milani C, Brentani MM, et al. Transcriptional profile of fibroblasts obtained from the primary site, lymph node and bone marrow of breast cancer patients. Genet Mol Biol 2014; 37(3): 480-9.
[http://dx.doi.org/10.1590/S1415-47572014000400002] [PMID: 25249769]
[18]
Chang YS, Huang HD, Yeh KT, Chang JG. Identification of novel mutations in endometrial cancer patients by whole-exome sequencing. Int J Oncol 2017; 50(5): 1778-84.
[http://dx.doi.org/10.3892/ijo.2017.3919] [PMID: 28339086]
[19]
Arai E, Sakamoto H, Ichikawa H, et al. Multilayer-omics analysis of renal cell carcinoma, including the whole exome, methylome and transcriptome. Int J Cancer 2014; 135(6): 1330-42.
[http://dx.doi.org/10.1002/ijc.28768] [PMID: 24504440]
[20]
Liu L, Ning Y, Yi J, et al. miR-6089/MYH9/β-catenin/c-Jun negative feedback loop inhibits ovarian cancer carcinogenesis and progression. Biomed Pharmacother 2020; 125: 109865.
[http://dx.doi.org/10.1016/j.biopha.2020.109865] [PMID: 32058212]
[21]
Liu L, Zeng Z, Yi J, et al. Expression and clinical significance of transcription factor 4 (TCF4) in epithelial ovarian cancer. Cancer Biomark 2019; 24(2): 213-21.
[http://dx.doi.org/10.3233/CBM-181849] [PMID: 30614797]
[22]
Goryunov D, Liem RK. Microtubule-actin cross-linking factor 1: domains, interaction partners, and tissue-specific functions. Methods Enzymol 2016; 569: 331-53.
[http://dx.doi.org/10.1016/bs.mie.2015.05.022] [PMID: 26778566]
[23]
Wang X, Jian X, Dou J, Wei Z, Zhao F. Decreasing microtubule actin cross-linking factor 1 inhibits melanoma metastasis by decreasing epithelial to mesenchymal transition. Cancer Manag Res 2020; 12: 663-73.
[http://dx.doi.org/10.2147/CMAR.S229156] [PMID: 32099463]
[24]
Kim R, Schell MJ, Teer JK, Greenawalt DM, Yang M, Yeatman TJ. Co-evolution of somatic variation in primary and metastatic colorectal cancer may expand biopsy indications in the molecular era. PLoS One 2015; 10(5): e0126670.
[http://dx.doi.org/10.1371/journal.pone.0126670] [PMID: 25974029]

Rights & Permissions Print Cite
Article Metrics
18
1
© 2024 Bentham Science Publishers | Privacy Policy